Skip to content

Study · Observational study · n = 1,177 · 2020

5 results

Treatment patterns, health resource utilization and costs among central precocious puberty patients treated with leuprolide or histrelin: an examination of the commercial and Medicaid populations.

Klein KO, Soliman AM, Bonafede M, Nelson JK, Grubb E

Journal of medical economics9 Dec 2019Cited by 4 (Europe PMC)

PMID31766907 (opens in a new tab)DOI10.1080/13696998.2019.1697700 (opens in a new tab)PepBankPUB-31766907
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyOther

    In commercially insured CPP patients, histrelin was linked to more healthcare services in general than leuprolide.

    In plain wordsIn commercially insured CPP patients, histrelin was linked to more healthcare services in general than leuprolide.

    Peptide
    Histrelin
    Outcome
    IncreaseCommercial healthcare service use
    Study

    n = 1,177

    Comparator
    Leuprolide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · year following treatment initiationAs given in this study (human).

    Source sentences

    Summary
    Commercially-insured patients treated with histrelin used more services in general than those treated with leuprolide but had fewer office visits.
    2 context sentences
    Summary · context
    A total of 1,177 commercially-insured (907 leuprolide and 270 histrelin) and 658 Medicaid-insured (613 leuprolide and 45 histrelin) patients were identified.
    Summary · context
    This retrospective cohort study identified commercial and Medicaid-insured CPP patients ≤12-years-old who were diagnosed between 1 January 2010 and 30 September 2014 and had ≥1 prescription for leuprolide or histrelin (first prescription = index date).
  2. 02HumanObservational studyOther

    In commercially insured CPP patients, histrelin was linked to fewer office visits than leuprolide.

    In plain wordsIn commercially insured CPP patients, histrelin was linked to fewer office visits than leuprolide.

    Peptide
    Histrelin
    Outcome
    DecreaseCommercial office visits
    Study

    n = 1,177

    Comparator
    Leuprolide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · year following treatment initiationAs given in this study (human).

    Source sentences

    Summary
    Commercially-insured patients treated with histrelin used more services in general than those treated with leuprolide but had fewer office visits.
    2 context sentences
    Summary · context
    A total of 1,177 commercially-insured (907 leuprolide and 270 histrelin) and 658 Medicaid-insured (613 leuprolide and 45 histrelin) patients were identified.
    Summary · context
    This retrospective cohort study identified commercial and Medicaid-insured CPP patients ≤12-years-old who were diagnosed between 1 January 2010 and 30 September 2014 and had ≥1 prescription for leuprolide or histrelin (first prescription = index date).
  3. 03HumanObservational studyOther

    In commercially insured CPP patients, costs were similar between histrelin and leuprolide groups.

    In plain wordsIn commercially insured CPP patients, costs were similar with histrelin and leuprolide.

    Peptide
    Histrelin
    Outcome
    Direction not reportedCommercial healthcare costs
    Study

    n = 1,177

    Comparator
    Leuprolide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · year following treatment initiationAs given in this study (human).

    Source sentences

    Summary
    In both payer populations, costs were similar.
    2 context sentences
    Summary · context
    A total of 1,177 commercially-insured (907 leuprolide and 270 histrelin) and 658 Medicaid-insured (613 leuprolide and 45 histrelin) patients were identified.
    Summary · context
    This retrospective cohort study identified commercial and Medicaid-insured CPP patients ≤12-years-old who were diagnosed between 1 January 2010 and 30 September 2014 and had ≥1 prescription for leuprolide or histrelin (first prescription = index date).
  4. 04HumanObservational studyOther

    In Medicaid-insured CPP patients, healthcare service use was similar between histrelin and leuprolide groups.

    In plain wordsIn Medicaid-insured CPP patients, healthcare service use was similar with histrelin and leuprolide.

    Peptide
    Histrelin
    Outcome
    Direction not reportedMedicaid healthcare service use
    Study

    n = 658

    Comparator
    Leuprolide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · year following treatment initiationAs given in this study (human).

    Source sentences

    Summary
    Healthcare service utilization was similar between Medicaid-insured treatment groups.
    2 context sentences
    Summary · context
    A total of 1,177 commercially-insured (907 leuprolide and 270 histrelin) and 658 Medicaid-insured (613 leuprolide and 45 histrelin) patients were identified.
    Summary · context
    This retrospective cohort study identified commercial and Medicaid-insured CPP patients ≤12-years-old who were diagnosed between 1 January 2010 and 30 September 2014 and had ≥1 prescription for leuprolide or histrelin (first prescription = index date).
  5. 05HumanObservational studyOther

    In Medicaid-insured CPP patients, costs were similar between histrelin and leuprolide groups.

    In plain wordsIn Medicaid-insured CPP patients, costs were similar with histrelin and leuprolide.

    Peptide
    Histrelin
    Outcome
    Direction not reportedMedicaid healthcare costs
    Study

    n = 658

    Comparator
    Leuprolide
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · year following treatment initiationAs given in this study (human).

    Source sentences

    Summary
    In both payer populations, costs were similar.
    2 context sentences
    Summary · context
    A total of 1,177 commercially-insured (907 leuprolide and 270 histrelin) and 658 Medicaid-insured (613 leuprolide and 45 histrelin) patients were identified.
    Summary · context
    This retrospective cohort study identified commercial and Medicaid-insured CPP patients ≤12-years-old who were diagnosed between 1 January 2010 and 30 September 2014 and had ≥1 prescription for leuprolide or histrelin (first prescription = index date).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.